{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T20:17:30Z","timestamp":1789676250162,"version":"4.0.1"},"reference-count":111,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrinology and Metabolism Clinics of North America"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ecl.2026.01.006","type":"journal-article","created":{"date-parts":[[2026,2,18]],"date-time":"2026-02-18T12:29:16Z","timestamp":1771417756000},"page":"345-363","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Diagnosis and Management of Adrenocortical Carcinoma"],"prefix":"10.1016","volume":"55","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9327-9615","authenticated-orcid":false,"given":"Vania","family":"Balderrama-Brondani","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4148-9637","authenticated-orcid":false,"given":"Mouhammed Amir","family":"Habra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib1","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1007\/s00268-005-0329-x","article-title":"Extent of disease at presentation and outcome for adrenocortical carcinoma: have we made progress?","volume":"30","author":"Kebebew","year":"2006","journal-title":"World J Surg"},{"issue":"8","key":"10.1016\/j.ecl.2026.01.006_bib2","doi-asserted-by":"crossref","first-page":"636","DOI":"10.14740\/jocmr3503w","article-title":"The characteristics and trends in adrenocortical carcinoma: a United States population based study","volume":"10","author":"Sharma","year":"2018","journal-title":"J Clin Med Res"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.006_bib3","doi-asserted-by":"crossref","first-page":"3145","DOI":"10.1002\/1097-0142(19931201)72:11<3145::AID-CNCR2820721105>3.0.CO;2-N","article-title":"Adrenal cortical carcinoma. Epidemiology and treatment with mitotane and a review of the literature","volume":"72","author":"Wooten","year":"1993","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib4","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.mce.2011.09.010","article-title":"Towards an understanding of the role of p53 in adrenocortical carcinogenesis","volume":"351","author":"Wasserman","year":"2012","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib5","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.eprac.2023.10.004","article-title":"Incidence and geographical distribution of adrenocortical carcinoma: retrospective analysis of a state cancer registry","volume":"30","author":"Balderrama-Brondani","year":"2024","journal-title":"Endocr Pract"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.006_bib6","first-page":"79","article-title":"Smoking and adrenal cancer mortality among United States veterans","volume":"5","author":"Chow","year":"1996","journal-title":"Cancer Epidemiol Biomarkers Prev"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib7","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1002\/(SICI)1097-0215(19960208)65:4<432::AID-IJC6>3.0.CO;2-Y","article-title":"Risk factors for adrenal cancer: an exploratory study","volume":"65","author":"Hsing","year":"1996","journal-title":"Int J Cancer"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib8","doi-asserted-by":"crossref","first-page":"1836","DOI":"10.1002\/ijc.32534","article-title":"Epidemiological risk factors for adrenocortical carcinoma: a hospital-based case-control study","volume":"146","author":"Habra","year":"2020","journal-title":"Int J Cancer"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.006_bib9","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1210\/er.2013-1029","article-title":"Adrenocortical carcinoma","volume":"35","author":"Else","year":"2014","journal-title":"Endocr Rev"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib10","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1530\/EJE-18-0608","article-title":"European Society of Endocrinology Clinical Practice Guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal tumors","volume":"179","author":"Fassnacht","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.006_bib11","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1002\/cncr.24030","article-title":"Limited prognostic value of the 2004 International Union against Cancer staging classification for adrenocortical carcinoma: proposal for a Revised TNM classification","volume":"115","author":"Fassnacht","year":"2009","journal-title":"Cancer"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib12","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1530\/EJE-18-0450","article-title":"Influence of hormonal functional status on survival in adrenocortical carcinoma: systematic review and meta-analysis","volume":"179","author":"Vanbrabant","year":"2018","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib13","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1210\/jc.2014-3182","article-title":"Major prognostic role of Ki67 in localized adrenocortical carcinoma after complete resection","volume":"100","author":"Beuschlein","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"17","key":"10.1016\/j.ecl.2026.01.006_bib14","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1056\/NEJM199004263221705","article-title":"Clinical features of adrenocortical carcinoma, prognostic factors, and the effect of mitotane therapy","volume":"322","author":"Luton","year":"1990","journal-title":"N Engl J Med"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib15","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1038\/nrendo.2010.235","article-title":"Adrenocortical carcinoma: a clinician\u2019s update","volume":"7","author":"Fassnacht","year":"2011","journal-title":"Nat Rev Endocrinol"},{"issue":"12","key":"10.1016\/j.ecl.2026.01.006_bib16","doi-asserted-by":"crossref","first-page":"3775","DOI":"10.1210\/jc.2011-1565","article-title":"Urine steroid metabolomics as a biomarker tool for detecting malignancy in adrenal tumors","volume":"96","author":"Arlt","year":"2011","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.006_bib17","doi-asserted-by":"crossref","first-page":"773","DOI":"10.1016\/S2213-8587(20)30218-7","article-title":"Urine steroid metabolomics for the differential diagnosis of adrenal incidentalomas in the EURINE-ACT study: a prospective test validation study","volume":"8","author":"Bancos","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib18","doi-asserted-by":"crossref","first-page":"88","DOI":"10.4329\/wjr.v5.i3.88","article-title":"Cross-sectional imaging work-up of adrenal masses","volume":"5","author":"Korivi","year":"2013","journal-title":"World J Radiol"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib19","doi-asserted-by":"crossref","first-page":"e2183","DOI":"10.1210\/clinem\/dgae781","article-title":"Clinical and radiological features of atypical adrenal Masses-A multicenter retrospective study","volume":"110","author":"Balderrama-Brondani","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib20","doi-asserted-by":"crossref","first-page":"531","DOI":"10.2214\/ajr.148.3.531","article-title":"Primary adrenocortical carcinoma: CT evaluation with clinical correlation","volume":"148","author":"Fishman","year":"1987","journal-title":"AJR Am J Roentgenol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib21","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1016\/j.crad.2011.03.023","article-title":"CT features and quantification of the characteristics of adrenocortical carcinomas on unenhanced and contrast-enhanced studies","volume":"67","author":"Zhang","year":"2012","journal-title":"Clin Radiol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib22","doi-asserted-by":"crossref","first-page":"201","DOI":"10.2214\/ajr.171.1.9648789","article-title":"Characterization of adrenal masses using unenhanced CT: an analysis of the CT literature","volume":"171","author":"Boland","year":"1998","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.006_bib23","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1210\/jc.2004-1627","article-title":"Clinical utility of noncontrast computed tomography attenuation value (hounsfield units) to differentiate adrenal adenomas\/hyperplasias from nonadenomas: Cleveland clinic experience","volume":"90","author":"Hamrahian","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib24","doi-asserted-by":"crossref","first-page":"577","DOI":"10.4158\/EP09351.OR","article-title":"Change in adrenal mass size as a predictor of a malignant tumor","volume":"16","author":"Pantalone","year":"2010","journal-title":"Endocr Pract"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib25","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.2214\/AJR.07.2799","article-title":"The incidental adrenal mass on CT: prevalence of adrenal disease in 1,049 consecutive adrenal masses in patients with no known malignancy","volume":"190","author":"Song","year":"2008","journal-title":"AJR Am J Roentgenol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.006_bib26","doi-asserted-by":"crossref","first-page":"107","DOI":"10.7326\/M18-3630","article-title":"Natural history of adrenal incidentalomas with and without mild autonomous cortisol excess: a systematic review and meta-analysis","volume":"171","author":"Elhassan","year":"2019","journal-title":"Ann Intern Med"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1530\/EC-21-0196","article-title":"Natural history of nonfunctioning adrenal incidentalomas: a 10-year longitudinal follow-up study","volume":"10","author":"Podbregar","year":"2021","journal-title":"Endocr Connect"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib28","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1093\/ejendo\/lvad066","article-title":"European society of Endocrinology clinical practice guidelines on the management of adrenal incidentalomas, in collaboration with the European Network for the Study of Adrenal tumors","volume":"189","author":"Fassnacht","year":"2023","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib29","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/j.surg.2005.05.014","article-title":"Adrenocortical carcinoma extending into the inferior vena cava: presentation of a 15-patient series and review of the literature","volume":"139","author":"Chiche","year":"2006","journal-title":"Surgery"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib30","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1210\/jc.2008-2302","article-title":"18F-Fluorodeoxyglucose positron emission tomography for the diagnosis of adrenocortical tumors: a prospective study in 77 operated patients","volume":"94","author":"Groussin","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib31","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1530\/EJE-15-0707","article-title":"18F-FDG PET\/CT in the post-operative monitoring of patients with adrenocortical carcinoma","volume":"173","author":"Ardito","year":"2015","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib32","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1007\/s12020-024-03695-6","article-title":"Prognostic role of quantitative [18F]FDG PET\/CT parameters in adrenocortical carcinoma","volume":"84","author":"Schlotelburg","year":"2024","journal-title":"Endocrine"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.006_bib33","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1007\/s00259-014-2834-3","article-title":"Impact of (1)(8)F-FDG PET\/CT on the management of adrenocortical carcinoma: analysis of 106 patients","volume":"41","author":"Takeuchi","year":"2014","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib34","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s12020-023-03568-4","article-title":"Contrast CT radiomic features add value to prediction of prognosis in adrenal cortical carcinoma","volume":"83","author":"Liu","year":"2024","journal-title":"Endocrine"},{"key":"10.1016\/j.ecl.2026.01.006_bib35","doi-asserted-by":"crossref","DOI":"10.1177\/17562872251352553","article-title":"Artificial intelligence and radiomics applications in adrenal lesions: a systematic review","volume":"17","author":"Ferro","year":"2025","journal-title":"Ther Adv Urol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib36","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1186\/s12880-025-01842-7","article-title":"Differentiating between adrenocortical carcinoma and pheochromocytoma by a CT-based radiomics model: a multicenter retrospective study","volume":"25","author":"Chao","year":"2025","journal-title":"BMC Med Imaging"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib37","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1177\/08465371251335170","article-title":"A computed tomography-based score to predict survival in patients with adrenocortical carcinoma: a proof-of-concept study","volume":"76","author":"Barat","year":"2025","journal-title":"Can Assoc Radiol J"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1097\/00000478-198403000-00001","article-title":"Comparative histologic study of 43 metastasizing and nonmetastasizing adrenocortical tumors","volume":"8","author":"Weiss","year":"1984","journal-title":"Am J Surg Pathol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib39","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1097\/00000478-198903000-00004","article-title":"Pathologic features of prognostic significance in adrenocortical carcinoma","volume":"13","author":"Weiss","year":"1989","journal-title":"Am J Surg Pathol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.006_bib40","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1007\/s12022-018-9525-8","article-title":"Immunohistochemical biomarkers of adrenal cortical neoplasms","volume":"29","author":"Mete","year":"2018","journal-title":"Endocr Pathol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib41","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1007\/s12022-022-09710-8","article-title":"Overview of the 2022 WHO classification of adrenal cortical tumors","volume":"33","author":"Mete","year":"2022","journal-title":"Endocr Pathol"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.006_bib42","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1093\/annonc\/mdv329","article-title":"Prognostic factors in stage III-IV adrenocortical carcinomas (ACC): an European Network for the Study of Adrenal Tumor (ENSAT) study","volume":"26","author":"Libe","year":"2015","journal-title":"Ann Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib43","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/S2213-8587(24)00378-4","article-title":"Adrenocortical carcinoma: a practical guide for clinicians","volume":"13","author":"Fassnacht","year":"2025","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib44","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1002\/1097-0142(19920101)69:1<66::AID-CNCR2820690113>3.0.CO;2-2","article-title":"Paraneoplastic Cushing\u2019s syndrome as an adverse prognostic factor in patients who die early with small cell lung cancer","volume":"69","author":"Dimopoulos","year":"1992","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib45","first-page":"42","article-title":"Cortisolemic indices predict severe infections in cushing syndrome due to ectopic production of adrenocorticotropin","volume":"85","author":"Sarlis","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib46","doi-asserted-by":"crossref","first-page":"R17","DOI":"10.1093\/ejendo\/lvaf017","article-title":"Delphi panel consensus on recommendations for thromboprophylaxis of venous thromboembolism in endogenous cushing\u2019s syndrome: a position statement","volume":"192","author":"Isand","year":"2025","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.006_bib47","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1530\/EC-20-0299","article-title":"Venous thromboembolism in patients with adrenocortical carcinoma after surgery","volume":"9","author":"Durmusoglu","year":"2020","journal-title":"Endocr Connect"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib48","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1093\/oncolo\/oyae099","article-title":"Venous thromboembolism in adrenocortical carcinoma: a retrospective analysis","volume":"29","author":"Lagana","year":"2024","journal-title":"Oncologist"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.006_bib49","doi-asserted-by":"crossref","DOI":"10.1530\/EC-25-0445","article-title":"Incidence and risk factors of venous thromboembolism in an adrenocortical carcinoma patient cohort","volume":"14","author":"Visser","year":"2025","journal-title":"Endocr Connect"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib50","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1530\/EJE-13-1033","article-title":"Transcutaneous biopsy of adrenocortical carcinoma is rarely helpful in diagnosis, potentially harmful, but does not affect patient outcome","volume":"170","author":"Williams","year":"2014","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.ecl.2026.01.006_bib51","doi-asserted-by":"crossref","first-page":"1261","DOI":"10.1002\/jso.26639","article-title":"Adrenal biopsy, as a diagnostic method, is associated with decreased overall survival in patients with T1\/T2 adrenocortical carcinoma: a propensity score-matched analysis","volume":"124","author":"Naffouje","year":"2021","journal-title":"J Surg Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib52","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.1210\/clinem\/dgac046","article-title":"Temporal trends in outcomes in patients with adrenocortical carcinoma: a multidisciplinary referral-center experience","volume":"107","author":"Daher","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.006_bib53","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1007\/s00464-010-0996-z","article-title":"Trends in adrenalectomy: a recent national review","volume":"24","author":"Murphy","year":"2010","journal-title":"Surg Endosc"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib54","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1016\/j.surg.2005.09.012","article-title":"Laparoscopic resection of adrenal cortical carcinoma: a cautionary note","volume":"138","author":"Gonzalez","year":"2005","journal-title":"Surgery"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib55","doi-asserted-by":"crossref","first-page":"1147","DOI":"10.1530\/EJE-09-1096","article-title":"Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?","volume":"162","author":"Leboulleux","year":"2010","journal-title":"Eur J Endocrinol"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib56","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1007\/s00268-010-0532-2","article-title":"Laparoscopic resection is inappropriate in patients with known or suspected adrenocortical carcinoma","volume":"34","author":"Miller","year":"2010","journal-title":"World J Surg"},{"issue":"12","key":"10.1016\/j.ecl.2026.01.006_bib57","doi-asserted-by":"crossref","first-page":"9288","DOI":"10.1007\/s00464-022-09167-0","article-title":"Operative approach and case volume are associated with negative resection margins for adrenocortical carcinoma","volume":"36","author":"Tseng","year":"2022","journal-title":"Surg Endosc"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib58","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1016\/j.eururo.2010.06.024","article-title":"Laparoscopic versus open adrenalectomy for adrenocortical carcinoma: surgical and oncologic outcome in 152 patients","volume":"58","author":"Brix","year":"2010","journal-title":"Eur Urol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib59","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.eururo.2010.01.036","article-title":"Retrospective evaluation of the outcome of open versus laparoscopic adrenalectomy for stage I and II adrenocortical cancer","volume":"57","author":"Porpiglia","year":"2010","journal-title":"Eur Urol"},{"key":"10.1016\/j.ecl.2026.01.006_bib60","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jss.2022.04.078","article-title":"Minimally invasive surgery for resectable adrenocortical carcinoma: a nationwide analysis","volume":"279","author":"Delman","year":"2022","journal-title":"J Surg Res"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib61","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1245\/s10434-015-4900-x","article-title":"Open versus laparoscopic adrenalectomy for adrenocortical carcinoma: a meta-analysis of surgical and oncological outcomes","volume":"23","author":"Autorino","year":"2016","journal-title":"Ann Surg Oncol"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.006_bib62","doi-asserted-by":"crossref","first-page":"4026","DOI":"10.1007\/s00464-013-3034-0","article-title":"Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?","volume":"27","author":"Cooper","year":"2013","journal-title":"Surg Endosc"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib63","doi-asserted-by":"crossref","first-page":"765","DOI":"10.1002\/1097-0142(195707\/08)10:4<765::AID-CNCR2820100423>3.0.CO;2-N","article-title":"Observations on adrenal carcinoma with special reference to the effects of amphenone","volume":"10","author":"Hertz","year":"1957","journal-title":"Cancer"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.006_bib64","doi-asserted-by":"crossref","first-page":"3895","DOI":"10.1210\/en.2015-1367","article-title":"Mitotane inhibits Sterol-O-Acyl transferase 1 triggering lipid-mediated endoplasmic reticulum stress and apoptosis in adrenocortical carcinoma cells","volume":"156","author":"Sbiera","year":"2015","journal-title":"Endocrinology"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib65","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1111\/j.1365-2265.2011.04214.x","article-title":"Drug interactions with mitotane by induction of CYP3A4 metabolism in the clinical management of adrenocortical carcinoma","volume":"75","author":"Kroiss","year":"2011","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"23","key":"10.1016\/j.ecl.2026.01.006_bib66","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1056\/NEJMoa063360","article-title":"Adjuvant mitotane treatment for adrenocortical carcinoma","volume":"356","author":"Terzolo","year":"2007","journal-title":"N Engl J Med"},{"issue":"23","key":"10.1016\/j.ecl.2026.01.006_bib67","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1056\/NEJMoa1200966","article-title":"Combination chemotherapy in advanced adrenocortical carcinoma","volume":"366","author":"Fassnacht","year":"2012","journal-title":"N Engl J Med"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.006_bib68","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1016\/S2213-8587(23)00193-6","article-title":"Adjuvant mitotane versus surveillance in low-grade, localised adrenocortical carcinoma (ADIUVO): an international, multicentre, open-label, randomised, phase 3 trial and observational study","volume":"11","author":"Terzolo","year":"2023","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib69","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1530\/EJE-13-0242","article-title":"Mitotane levels predict the outcome of patients with adrenocortical carcinoma treated adjuvantly following radical resection","volume":"169","author":"Terzolo","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib70","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1016\/j.eprac.2024.11.007","article-title":"Comprehensive analysis of mitotane-related adverse events using the Food and Drug Administration adverse event reporting system","volume":"31","author":"Wang","year":"2025","journal-title":"Endocr Pract"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib71","doi-asserted-by":"crossref","first-page":"G15","DOI":"10.1093\/ejendo\/lvae038","article-title":"International consensus on mitotane treatment in pediatric patients with adrenal cortical tumors: indications, therapy, and management of adverse effects","volume":"190","author":"Riedmeier","year":"2024","journal-title":"Eur J Endocrinol"},{"issue":"9","key":"10.1016\/j.ecl.2026.01.006_bib72","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1038\/s41416-021-01513-8","article-title":"Adjuvant platinum-based chemotherapy in radically resected adrenocortical carcinoma: a cohort study","volume":"125","author":"Kimpel","year":"2021","journal-title":"Br J Cancer"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib73","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.amjsurg.2020.10.038","article-title":"Analysis of adjuvant chemotherapy in patients undergoing curative-intent resection of localized adrenocortical carcinoma","volume":"222","author":"Al Asadi","year":"2021","journal-title":"Am J Surg"},{"issue":"11","key":"10.1016\/j.ecl.2026.01.006_bib74","doi-asserted-by":"crossref","first-page":"4501","DOI":"10.1210\/jc.2006-1007","article-title":"Efficacy of adjuvant radiotherapy of the tumor bed on local recurrence of adrenocortical carcinoma","volume":"91","author":"Fassnacht","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib75","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1530\/EJE-13-0519","article-title":"Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center","volume":"169","author":"Ayala-Ramirez","year":"2013","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"10.1016\/j.ecl.2026.01.006_bib76","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","article-title":"Adjuvant radiation therapy improves local control after surgical resection in patients with localized adrenocortical carcinoma","volume":"92","author":"Sabolch","year":"2015","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib77","doi-asserted-by":"crossref","first-page":"2060","DOI":"10.1245\/s10434-018-6510-x","article-title":"Adjuvant radiation is associated with improved survival for select patients with non-metastatic adrenocortical carcinoma","volume":"25","author":"Nelson","year":"2018","journal-title":"Ann Surg Oncol"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib78","doi-asserted-by":"crossref","first-page":"1318","DOI":"10.1007\/s00268-014-2484-4","article-title":"Borderline resectable adrenal cortical carcinoma: a potential role for preoperative chemotherapy","volume":"38","author":"Bednarski","year":"2014","journal-title":"World J Surg"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib80","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/wjs.12014","article-title":"Surgical management of metastatic adrenocortical carcinoma","volume":"48","author":"Passman","year":"2024","journal-title":"World J Surg"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib81","doi-asserted-by":"crossref","first-page":"964","DOI":"10.1210\/clinem\/dgab865","article-title":"Cytoreductive surgery of the primary tumor in metastatic adrenocortical carcinoma: impact on patients\u2019 survival","volume":"107","author":"Srougi","year":"2022","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib82","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/1097-0142(20010915)92:6<1385::AID-CNCR1461>3.0.CO;2-2","article-title":"Impact of monitoring plasma 1,1-dichlorodiphenildichloroethane (o,p\u2019DDD) levels on the treatment of patients with adrenocortical carcinoma","volume":"92","author":"Baudin","year":"2001","journal-title":"Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib83","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1210\/jc.2017-02591","article-title":"Mitotane monotherapy in patients with advanced adrenocortical carcinoma","volume":"103","author":"Megerle","year":"2018","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.006_bib84","doi-asserted-by":"crossref","first-page":"3495","DOI":"10.1210\/jc.2012-1419","article-title":"Sunitinib in refractory adrenocortical carcinoma: a phase II, single-arm, open-label trial","volume":"97","author":"Kroiss","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.1016\/j.ecl.2026.01.006_bib85","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1530\/EJE-11-0918","article-title":"Phase II study of weekly paclitaxel and sorafenib as second\/third-line therapy in patients with adrenocortical carcinoma","volume":"166","author":"Berruti","year":"2012","journal-title":"Eur J Endocrinol"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib86","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1210\/jc.2013-2298","article-title":"The VEGF inhibitor axitinib has limited effectiveness as a therapy for adrenocortical cancer","volume":"99","author":"O'Sullivan","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib87","doi-asserted-by":"crossref","first-page":"649","DOI":"10.1016\/S1470-2045(24)00095-0","article-title":"Cabozantinib monotherapy for advanced adrenocortical carcinoma: a single-arm, phase 2 trial","volume":"25","author":"Campbell","year":"2024","journal-title":"Lancet Oncol"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib88","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1530\/EJE-10-0956","article-title":"Mitotane has a strong and a durable inducing effect on CYP3A4 activity","volume":"164","author":"van Erp","year":"2011","journal-title":"Eur J Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib89","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1200\/JCO.19.01586","article-title":"PD-1 blockade in advanced adrenocortical carcinoma","volume":"38","author":"Raj","year":"2020","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib90","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1186\/s40425-019-0722-x","article-title":"Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma","volume":"7","author":"Habra","year":"2019","journal-title":"J Immunother Cancer"},{"issue":"21","key":"10.1016\/j.ecl.2026.01.006_bib91","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1056\/NEJMoa1501824","article-title":"Pembrolizumab for the treatment of non-small-cell lung cancer","volume":"372","author":"Garon","year":"2015","journal-title":"N Engl J Med"},{"issue":"19","key":"10.1016\/j.ecl.2026.01.006_bib92","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-Positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib93","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib94","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0013","article-title":"Safety and efficacy of pembrolizumab monotherapy in patients with previously treated advanced gastric and gastroesophageal junction cancer: phase 2 clinical KEYNOTE-059 trial","volume":"4","author":"Fuchs","year":"2018","journal-title":"JAMA Oncol"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib95","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1093\/annonc\/mdz135","article-title":"Antitumor activity and safety of pembrolizumab in patients with advanced recurrent ovarian cancer: results from the phase II KEYNOTE-100 study","volume":"30","author":"Matulonis","year":"2019","journal-title":"Ann Oncol"},{"issue":"6349","key":"10.1016\/j.ecl.2026.01.006_bib96","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1126\/science.aan6733","article-title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","volume":"357","author":"Le","year":"2017","journal-title":"Science"},{"issue":"26","key":"10.1016\/j.ecl.2026.01.006_bib97","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib98","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1186\/s40425-018-0424-9","article-title":"Avelumab in patients with previously treated metastatic adrenocortical carcinoma: phase 1b results from the JAVELIN solid tumor trial","volume":"6","author":"Le Tourneau","year":"2018","journal-title":"J Immunother Cancer"},{"issue":"12","key":"10.1016\/j.ecl.2026.01.006_bib99","doi-asserted-by":"crossref","first-page":"6193","DOI":"10.1210\/jc.2019-00600","article-title":"Nivolumab in metastatic adrenocortical carcinoma: results of a phase 2 trial","volume":"104","author":"Carneiro","year":"2019","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib100","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2021.1908771","article-title":"Combination immunotherapy with ipilimumab and nivolumab in patients with advanced adrenocortical carcinoma: a subgroup analysis of CA209-538","volume":"10","author":"Klein","year":"2021","journal-title":"OncoImmunology"},{"issue":"6","key":"10.1016\/j.ecl.2026.01.006_bib101","doi-asserted-by":"crossref","first-page":"840","DOI":"10.1002\/cncr.33328","article-title":"Results of a multicenter, phase 2 study of nivolumab and ipilimumab for patients with advanced rare genitourinary malignancies","volume":"127","author":"McGregor","year":"2021","journal-title":"Cancer"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib102","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2024-009074","article-title":"Phase II basket trial of dual Anti-CTLA-4 and Anti-PD-1 blockade in rare tumors (DART) SWOG S1609: adrenocortical carcinoma cohort","volume":"12","author":"Patel","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"22","key":"10.1016\/j.ecl.2026.01.006_bib103","doi-asserted-by":"crossref","first-page":"4655","DOI":"10.1158\/1078-0432.CCR-25-2143","article-title":"Cabozantinib plus atezolizumab in advanced, progressive endocrine malignancies: a multi-cohort, basket, phase II trial (CABATEN\/GETNE-T1914)","volume":"31","author":"Capdevila","year":"2025","journal-title":"Clin Cancer Res"},{"issue":"10","key":"10.1016\/j.ecl.2026.01.006_bib104","doi-asserted-by":"crossref","first-page":"850","DOI":"10.1093\/oncolo\/oyae130","article-title":"Clinical outcomes of image-guided therapies in patients with adrenocortical carcinoma: a tertiary referral center retrospective study","volume":"29","author":"Chahla","year":"2024","journal-title":"Oncologist"},{"issue":"7","key":"10.1016\/j.ecl.2026.01.006_bib105","doi-asserted-by":"crossref","first-page":"2259","DOI":"10.1002\/cam4.3740","article-title":"Long-term outcomes in patients with advanced adrenocortical carcinoma after image-guided locoregional ablation or embolization","volume":"10","author":"Mauda-Havakuk","year":"2021","journal-title":"Cancer Med"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib106","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1038\/s41416-022-02082-0","article-title":"Efficacy and safety of radiation therapy in advanced adrenocortical carcinoma","volume":"128","author":"Kimpel","year":"2023","journal-title":"Br J Cancer"},{"issue":"4","key":"10.1016\/j.ecl.2026.01.006_bib107","doi-asserted-by":"crossref","first-page":"706","DOI":"10.3390\/cancers16040706","article-title":"The value of local therapies in advanced adrenocortical carcinoma","volume":"16","author":"Kimpel","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib108","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1055\/a-2209-6022","article-title":"Current evidence on local therapies in advanced adrenocortical carcinoma","volume":"56","author":"Kimpel","year":"2024","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.ecl.2026.01.006_bib109","doi-asserted-by":"crossref","DOI":"10.1016\/j.mce.2024.112272","article-title":"Cellular landscape of adrenocortical carcinoma at single-nuclei resolution","volume":"590","author":"Tourigny","year":"2024","journal-title":"Mol Cell Endocrinol"},{"issue":"1","key":"10.1016\/j.ecl.2026.01.006_bib110","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1186\/s12964-025-02115-0","article-title":"Emerging role of IGF1R and IR expression and localisation in adrenocortical carcinomas","volume":"23","author":"Catalano","year":"2025","journal-title":"Cell Commun Signal"},{"key":"10.1016\/j.ecl.2026.01.006_bib111","article-title":"CAR T cells redirected to B7-H3 for pediatric solid tumors: current status and future perspectives","volume":"3","author":"Epperly","year":"2024","journal-title":"EJC Paediatr Oncol"},{"issue":"5","key":"10.1016\/j.ecl.2026.01.006_bib112","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s11912-023-01380-x","article-title":"CAR-T therapies in solid tumors: opportunities and challenges","volume":"25","author":"Guzman","year":"2023","journal-title":"Curr Oncol Rep"}],"container-title":["Endocrinology and Metabolism Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985292600006X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S088985292600006X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:51:03Z","timestamp":1781621463000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S088985292600006X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":111,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["S088985292600006X"],"URL":"https:\/\/doi.org\/10.1016\/j.ecl.2026.01.006","relation":{},"ISSN":["0889-8529"],"issn-type":[{"value":"0889-8529","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Diagnosis and Management of Adrenocortical Carcinoma","name":"articletitle","label":"Article Title"},{"value":"Endocrinology and Metabolism Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ecl.2026.01.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}